Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Chemotherapy, Personalized

Key genes can predict sensitivity to toxin

Genetic tests can indicate whether a given person is at risk for certain diseases. But recent work by MIT scientists suggests that it may soon be possible to test how well people will tolerate toxic compounds, as well. Such tests could even enable doctors to predict how a given patient will respond to specific chemo­therapy drugs.

The scientists, led by Leona Samson, director of MIT’s Center for Environmental Health Sciences and professor of biological engineering and biology, first measured gene expression in cells from 24 healthy people in a genetically and ethnically diverse population sample. Then they exposed these cell lines to a DNA-damaging agent, MNNG. By comparing gene expression in the four most sensitive and the four most resistant cell lines, they were able to zero in on 48 key genes correlated with MNNG sensitivity. By measuring the activity of these standouts alone, without examining every gene, they found that they could predict, with 94 percent accuracy, whether any of the remaining cell lines would stand up to the toxic compound. Because the cell lines came from a diverse group of subjects, the test should be widely applicable in the general population.

This story is part of the March/April 2009 Issue of the MIT News Magazine
See the rest of the issue
Subscribe

Samson says that the group already knew of a dozen genes linked to MNNG resistance, but this study scanned for all potential candidates, identifying 450 that were differently expressed. “We found an incredible number,” she says. “That made us realize that there are a whole lot of other things going on that are important for protecting against damaging agents.”

MNNG was an ideal test subject because it’s similar to toxic compounds found in common chemotherapy drugs and tobacco smoke. Now Samson’s group is expanding the study to chemotherapeutic agents. She hopes that in the long run, the group’s work will lead to tests that can determine which drugs will be most effective in killing a particular tumor and, just as important, how well a patient’s healthy cells will resist that compound’s toxic action. “You want to kill the tumor but you don’t want to kill the person,” Samson says. And while she’s hesitant to speculate, she’s hopeful about the potential of the work: “The important thing is finding the most effective treatment for each individual patient. It’s really thinking toward the possibility of personalized medicine.”

The latest Insider Conversation is live! Listen to the story behind the story.

Subscribe today
Already a Premium subscriber? Log in.

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

Want more award-winning journalism? Subscribe to Insider Basic.
  • Insider Basic {! insider.prices.basic !}*

    {! insider.display.menuOptionsLabel !}

    Six issues of our award winning print magazine, unlimited online access plus The Download with the top tech stories delivered daily to your inbox.

    See details+

    What's Included

    Unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Bimonthly print magazine (6 issues per year)

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.